Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components
Transfusion · 2026-01 · 66 (1) · 18-23
DOI: 10.1111/trf.18485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 26.11.2025. Verfasst von Briana Greenwall und 2 weiteren Autor:innen. Beteiligte Einrichtung: ARUP Laboratories, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Plasma, Testosterone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Cerus Corporation.
Abstract (Originalsprache)
Background
Blood donor eligibility policies may exclude individuals based on medication use, but the donor health questionnaire may not reliably capture all prescriptions. This study evaluates the capacity of the compound adsorption device (CAD) within the INTERCEPT Blood System Pathogen Reduction Technology (PRT) for plasma to remove exogenous testosterone and high doses of two drugs on the FDA donor deferral list. Study Design and Methods Plasma was manufactured from male whole blood donors undergoing testosterone replacement therapy (TRT) or whole blood donors with no medication history to be supplemented with supratherapeutic concentrations of apixaban, a common anticoagulant, and escalating doses of emtricitabine and tenofovir (FTC&TFV) to note any saturating effects of removal. Plasma units were treated with INTERCEPT PRT only using the amotosalen and CAD steps without photochemical activation. Quantitative assays analyzed pre‐ and post‐CAD samples. Statistical analysis was performed using a Wilcoxon signed‐rank test and one‐way ANOVA.
Results
The CAD reduced the mean free and total testosterone by 75% (pre‐CAD 107.4, post‐CAD 26.8 pg/mL) and 74% (pre‐CAD 352.2, post‐CAD 85.7 ng/mL), respectively. Apixaban was removed below the limit of detection (pre‐CAD mean 420, post‐CAD mean
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ARUP Laboratories, Salt Lake City, Utah, USA.
- University of Utah, Salt Lake City, Utah, USA.
Förderung
- NIAID NIH HHS
- Cerus Corporation
Zitieren
APA
Greenwall, B., Reeder, K., & Anani, W. Q. (2026). Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components. Transfusion, 66(1), 18-23. https://doi.org/10.1111/trf.18485
Vancouver
Greenwall B, Reeder K, Anani WQ. Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components. Transfusion. 2026;66(1):18-23. doi:10.1111/trf.18485
BibTeX
@article{Greenwall2026,
author = {Greenwall, Briana and Reeder, Kathryn and Anani, Waseem Qais},
title = {Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {1},
pages = {18--23},
doi = {10.1111/trf.18485}
}
EUVIMED